SpectRx, Inc. Announces New SimpleChoice(R) twist and twist Pro Insulin Pump Infusion Sets with Shortest Catheter on the Market

SpectRx, Inc. (OTCBB: SPRX) today announced the
immediate availability of the new SimpleChoice(R) twist and twist Pro
insulin pump infusion sets with 5 mm catheters. The new products were
introduced at the American Association of Diabetes Educators (AADE)
2006 annual meeting in Los Angeles.
   The less invasive catheters are the shortest on the market and are
designed for ease of insertion and for a more comfortable wearing
experience for people with diabetes who use insulin pumps. The twist
product line also features the only 360-degree rotating design on the
market for maximum movement.
   "Now for the first time, all pump users have an opportunity to
improve the quality of their pump wearing experience by switching to
the new, less invasive, SimpleChoice twist and twist Pro infusion sets
with 360-degree rotation," said Bill Arthur, SpectRx, Inc. president
and chief operating officer. "The freedom of movement provided by the
360-degree rotating design, combined with the shortest catheter on the
market, makes the twist the infusion set product for pump wearers
seeking comfort and mobility. The set should also increase the appeal
of our SimpleChoice product line and enhance our efforts to seek a
strategic partner to help grow our insulin-delivery business."
   The SimpleChoice(R) twist Pro is for use with Medtronic(R)
Paradigm brand insulin pumps. The SimpleChoice(R) twist is for use
with all other Medtronic(R) pumps as well as all makes of Deltec(R),
Animas(R), and Disetronic(R) insulin pumps. Visit
www.mysimplechoice.com, or call 877-773-2879 for information on where
to buy the new shorter SimpleChoice(R) twist and twist Pro.
   Insulin infusion sets are for use with insulin pumps worn by
people with diabetes to help control their glucose levels. The
disposable infusion sets are changed about every three days. Catheters
are the small tubing that delivers insulin under the skin. More than
13 million Americans have been diagnosed with diabetes.

   About SpectRx, Inc.

   SpectRx, Inc. (OTCBB: SPRX) is a diabetes management company
developing and providing innovative solutions for insulin delivery and
glucose monitoring. SpectRx markets the SimpleChoice(R) line of
innovative diabetes management products, which include insulin pump
disposable supplies. SpectRx also plans to develop a consumer device
for continuous glucose monitoring. The company is commercializing its
non-invasive cervical cancer detection technology through its
subsidiary Guided Therapeutics, Inc., which SpectRx intends to
separately finance. For more information, visit SpectRx's web sites at
spectrx.com, mysimplechoice.com and guidedtherapeutics.com.

   Trademarks are owned by their respective companies.

   "Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995. A number of the matters and subject areas
discussed in this news release that are not historical or current
facts deal with potential future circumstances and developments. The
discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from SpectRx's actual future
experience involving any of or more of such matters and subject areas.
Such risks and uncertainties include: the early stage of products in
development, the uncertainty of market acceptance of products, the
uncertainty of development or effectiveness of distribution channels,
the intense competition in the medical device industry, the
uncertainty of capital to develop products, the uncertainty of
regulatory approval of products, dependence on licensed intellectual
property, as well as those that are more fully described from time to
time under the heading "Risk Factors" in SpectRx's reports filed with
the SEC, including SpectRx's Annual Report on Form 10-KSB for the
fiscal year ended December 31, 2005, as amended, and subsequent
quarterly reports.